Roquefort Therapeutics (LON:ROQ) Trading Up 15.6% – Should You Buy?

Roquefort Therapeutics plc (LON:ROQ) shares traded up 15.6% during trading on Thursday . The company traded as high as GBX 1.85 and last traded at GBX 1.85. 993,554 shares changed hands during trading, a decline of 52% from the average session volume of 2,054,428 shares. The stock had previously closed at GBX 1.60.

Roquefort Therapeutics Trading Up 15.6%

The firm has a market cap of £2.91 million, a price-to-earnings ratio of -2.94 and a beta of 0.05. The business has a 50 day moving average of GBX 1.94 and a 200 day moving average of GBX 1.70. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37.

Roquefort Therapeutics (LON:ROQ) last issued its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.33) EPS for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.